{
    "Overall_score": {
        "Correlation": 9,
        "Sentiment": 8,
        "Importance": 9,
        "Impact": 8,
        "Duration": 7,
        "Virality": 6,
        "Source_Score": 8,
        "Specificity": 9,
        "Sector_Spread": 5,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "Strong trial results for Novartis' chronic heart failure drug LCZ696. 20% c/v mortality relative risk reduction.",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 4,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 5,
            "Tech_Mentions": 3
        },
        {
            "News_content": "Nice 3-minute video from NEJM summarizes LCZ696 PARADIGM-HF findings. #ESCCongress",
            "Correlation": 8,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 8,
            "Source_Score": 9,
            "Specificity": 7,
            "Sector_Spread": 4,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Strong trial results for Novartis' chronic heart failure drug LCZ696. 20% c/v mortality relative risk reduction.",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 4,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 5,
            "Tech_Mentions": 3
        }
    ]
}